Multi-Antigen Viral-Vectored Vaccine Protects Against SARS-CoV-2 and Variants in a Lethal hACE2 Transgenic Mouse Model

Widespread and rapidly evolving SARS-CoV-2 posed an unprecedented challenge to vaccine developers. GeoVax has designed a multiantigen SARS-CoV-2 vaccine, designated GEO-CM02 based on a Modified Vaccinia Virus (MVA) vector that expresses spike (S), membrane (M), and envelope (E) antigens. This experi...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 13; no. 4; p. 411
Main Authors Stone, Shannon, Elsharkawy, Amany, Burleson, J. D., Hauser, Mary, Domi, Arban, Kumari, Pratima, Nabi, Zainab, Natekar, Janhavi P., Porto, Maciel, Backstedt, Brian, Newman, Mark, Oruganti, Sreenivasa Rao, Kumar, Mukesh
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 15.04.2025
MDPI
Subjects
Animals
Antibodies
Antigens
COVID-19
COVID-19 vaccines
Effectiveness
Enzymes
Genes
Immune response
Immunogenicity
Infections
Lungs
Lymphocytes
Lymphocytes T
Microscopy
MVA-VLP
Olfactory bulb
Peptides
Proteins
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Transgenic mice
Vaccine efficacy
Vaccines
Viral diseases
Viruses
United States
COVID-19
SARS-CoV-2
MVA-VLP
Online AccessGet full text

Cover

Abstract Widespread and rapidly evolving SARS-CoV-2 posed an unprecedented challenge to vaccine developers. GeoVax has designed a multiantigen SARS-CoV-2 vaccine, designated GEO-CM02 based on a Modified Vaccinia Virus (MVA) vector that expresses spike (S), membrane (M), and envelope (E) antigens. This experimental vaccine was tested in the hACE2 transgenic mouse model to assess immunogenicity and efficacy. Administration of the vaccine in a two-dose regimen elicited high levels of neutralizing antibodies and provided complete protection, effectively reducing lung, olfactory bulb, and brain viral load and reducing lung inflammation following infection with original B.1 virus and the B.1.1.529 variant. In addition, GEO-CM02 conferred 80% protection against a lethal infection with the B.1.351 variant. GEO-CM02 vaccine efficacy studies also demonstrated a complete level of vaccine-induced protection with a single dose against the original B.1 virus and B.1.1.529 variant. GEO-CM02 effectively elicited functional T-cell responses in both prime and prime–boost groups. These data indicate that vaccination with the GEO-CM02 vaccine can induce immune responses that protect against severe disease induced by SARS-CoV-2 and its variants in a highly relevant pre-clinical model.
AbstractList Widespread and rapidly evolving SARS-CoV-2 posed an unprecedented challenge to vaccine developers. GeoVax has designed a multiantigen SARS-CoV-2 vaccine, designated GEO-CM02 based on a Modified Vaccinia Virus (MVA) vector that expresses spike (S), membrane (M), and envelope (E) antigens. This experimental vaccine was tested in the hACE2 transgenic mouse model to assess immunogenicity and efficacy. Administration of the vaccine in a two-dose regimen elicited high levels of neutralizing antibodies and provided complete protection, effectively reducing lung, olfactory bulb, and brain viral load and reducing lung inflammation following infection with original B.1 virus and the B.1.1.529 variant. In addition, GEO-CM02 conferred 80% protection against a lethal infection with the B.1.351 variant. GEO-CM02 vaccine efficacy studies also demonstrated a complete level of vaccine-induced protection with a single dose against the original B.1 virus and B.1.1.529 variant. GEO-CM02 effectively elicited functional T-cell responses in both prime and prime–boost groups. These data indicate that vaccination with the GEO-CM02 vaccine can induce immune responses that protect against severe disease induced by SARS-CoV-2 and its variants in a highly relevant pre-clinical model.
Widespread and rapidly evolving SARS-CoV-2 posed an unprecedented challenge to vaccine developers. GeoVax has designed a multiantigen SARS-CoV-2 vaccine, designated GEO-CM02 based on a Modified Vaccinia Virus (MVA) vector that expresses spike (S), membrane (M), and envelope (E) antigens. This experimental vaccine was tested in the hACE2 transgenic mouse model to assess immunogenicity and efficacy. Administration of the vaccine in a two-dose regimen elicited high levels of neutralizing antibodies and provided complete protection, effectively reducing lung, olfactory bulb, and brain viral load and reducing lung inflammation following infection with original B.1 virus and the B.1.1.529 variant. In addition, GEO-CM02 conferred 80% protection against a lethal infection with the B.1.351 variant. GEO-CM02 vaccine efficacy studies also demonstrated a complete level of vaccine-induced protection with a single dose against the original B.1 virus and B.1.1.529 variant. GEO-CM02 effectively elicited functional T-cell responses in both prime and prime-boost groups. These data indicate that vaccination with the GEO-CM02 vaccine can induce immune responses that protect against severe disease induced by SARS-CoV-2 and its variants in a highly relevant pre-clinical model.Widespread and rapidly evolving SARS-CoV-2 posed an unprecedented challenge to vaccine developers. GeoVax has designed a multiantigen SARS-CoV-2 vaccine, designated GEO-CM02 based on a Modified Vaccinia Virus (MVA) vector that expresses spike (S), membrane (M), and envelope (E) antigens. This experimental vaccine was tested in the hACE2 transgenic mouse model to assess immunogenicity and efficacy. Administration of the vaccine in a two-dose regimen elicited high levels of neutralizing antibodies and provided complete protection, effectively reducing lung, olfactory bulb, and brain viral load and reducing lung inflammation following infection with original B.1 virus and the B.1.1.529 variant. In addition, GEO-CM02 conferred 80% protection against a lethal infection with the B.1.351 variant. GEO-CM02 vaccine efficacy studies also demonstrated a complete level of vaccine-induced protection with a single dose against the original B.1 virus and B.1.1.529 variant. GEO-CM02 effectively elicited functional T-cell responses in both prime and prime-boost groups. These data indicate that vaccination with the GEO-CM02 vaccine can induce immune responses that protect against severe disease induced by SARS-CoV-2 and its variants in a highly relevant pre-clinical model.
Audience Academic
Author Newman, Mark
Porto, Maciel
Burleson, J. D.
Stone, Shannon
Domi, Arban
Backstedt, Brian
Natekar, Janhavi P.
Hauser, Mary
Nabi, Zainab
Kumari, Pratima
Oruganti, Sreenivasa Rao
Kumar, Mukesh
Elsharkawy, Amany
AuthorAffiliation 1 Department of Biology, Georgia State University, Atlanta, GA 30303, USA; sstone12@student.gsu.edu (S.S.); aelsharkawy2@student.gsu.edu (A.E.); znabi1@gsu.edu (Z.N.); jnatekar1@student.gsu.edu (J.P.N.)
2 GeoVax, Inc., Atlanta, GA 30080, USA; jburleson@geovax.com (J.D.B.); mhauser@geovax.com (M.H.); adomi@geovax.com (A.D.); pkumari@geovax.com (P.K.); mnewman@geovax.com (M.N.)
3 BioQual, Inc., Rockville, MD 20850, USA; mporto@bioqual.com (M.P.); bbackstedt@bioqual.com (B.B.)
AuthorAffiliation_xml – name: 1 Department of Biology, Georgia State University, Atlanta, GA 30303, USA; sstone12@student.gsu.edu (S.S.); aelsharkawy2@student.gsu.edu (A.E.); znabi1@gsu.edu (Z.N.); jnatekar1@student.gsu.edu (J.P.N.)
– name: 2 GeoVax, Inc., Atlanta, GA 30080, USA; jburleson@geovax.com (J.D.B.); mhauser@geovax.com (M.H.); adomi@geovax.com (A.D.); pkumari@geovax.com (P.K.); mnewman@geovax.com (M.N.)
– name: 3 BioQual, Inc., Rockville, MD 20850, USA; mporto@bioqual.com (M.P.); bbackstedt@bioqual.com (B.B.)
Author_xml – sequence: 1
  givenname: Shannon
  orcidid: 0000-0003-2314-3437
  surname: Stone
  fullname: Stone, Shannon
– sequence: 2
  givenname: Amany
  orcidid: 0009-0003-3645-5605
  surname: Elsharkawy
  fullname: Elsharkawy, Amany
– sequence: 3
  givenname: J. D.
  surname: Burleson
  fullname: Burleson, J. D.
– sequence: 4
  givenname: Mary
  surname: Hauser
  fullname: Hauser, Mary
– sequence: 5
  givenname: Arban
  surname: Domi
  fullname: Domi, Arban
– sequence: 6
  givenname: Pratima
  surname: Kumari
  fullname: Kumari, Pratima
– sequence: 7
  givenname: Zainab
  surname: Nabi
  fullname: Nabi, Zainab
– sequence: 8
  givenname: Janhavi P.
  surname: Natekar
  fullname: Natekar, Janhavi P.
– sequence: 9
  givenname: Maciel
  surname: Porto
  fullname: Porto, Maciel
– sequence: 10
  givenname: Brian
  surname: Backstedt
  fullname: Backstedt, Brian
– sequence: 11
  givenname: Mark
  surname: Newman
  fullname: Newman, Mark
– sequence: 12
  givenname: Sreenivasa Rao
  surname: Oruganti
  fullname: Oruganti, Sreenivasa Rao
– sequence: 13
  givenname: Mukesh
  orcidid: 0000-0003-0970-4875
  surname: Kumar
  fullname: Kumar, Mukesh
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40333327$$D View this record in MEDLINE/PubMed
BookMark eNptklFrFDEQxxep2Fr77pMs-OLL1mST3SRPchxVC1cUWw_fwmx2cpdjL2mTvQO_vblerb3iDCRh5pf_MMO8Lo588FgUbyk5Z0yRj1swxnlMlBFOOKUvipOaiLZiiv06evI-Ls5SWpFsijLZilfFMScsWy1Oiu3VZhhdNfGjW6Av5y7CUM3RjCFiX873JcrvMYw5lsrJApxPY3k9-XFdTcO8qkvwOy468DnvfAnlDMclDOVyMr2oy5sIPmVpZ8qrsEmYzx6HN8VLC0PCs4f7tPj5-eJm-rWafftyOZ3MKtNQNlbQCyGYAkJr2fVNqxoUBJgFqZCDbGXTouASgELDaNPY2qqWCjDSIpHEstPicq_bB1jp2-jWEH_rAE7fB0JcaIijMwNqLmtqe9bSrql5Y1vZWUu47RRFwk2HWevTXut2062xN-jHPKwD0cOMd0u9CFtNa8IopzwrfHhQiOFug2nUa5cMDgN4zLPRrCaUKUnu0ffP0FXYRJ9npRlVvOUy-z9qAbkD523Ihc1OVE8kE62iQolMnf-Hyt7j2pm8VNbl-MGHd087fWzx79pkgOwBE0NKEe0jQoneLad-vpzsD6r51VY
Cites_doi 10.1074/jbc.RA120.016175
10.1038/s41598-017-19041-y
10.1016/j.virol.2020.05.002
10.1007/s11684-020-0822-5
10.1038/s41598-017-08719-y
10.1016/j.cell.2020.08.017
10.1128/JVI.74.16.7651-7655.2000
10.1073/pnas.0403492101
10.1038/s41586-020-03041-6
10.1038/d41586-021-02177-3
10.3390/pathogens13070528
10.1038/s41541-020-00226-y
10.1186/1471-2172-9-15
10.1128/JVI.02667-12
10.3390/vaccines10030442
10.1056/NEJMoa2035389
10.1101/2020.12.14.422714
10.1016/j.virol.2006.02.039
10.1016/j.celrep.2021.108728
10.1016/S2666-5247(23)00255-0
10.1016/j.bsheal.2022.07.001
10.1093/infdis/jiq105
10.1002/eji.202048908
10.1056/NEJMc2206576
10.1038/s41598-017-15039-8
10.1016/j.cell.2023.04.007
10.3389/fbioe.2020.00862
10.3389/fimmu.2022.827605
10.1101/2023.01.03.519511
10.1128/JVI.74.2.923-933.2000
10.1016/j.cell.2020.09.038
10.3389/fmicb.2024.1466980
10.1038/s41586-022-04980-y
10.1038/s41541-022-00436-6
10.3389/fimmu.2020.01100
10.1128/jvi.00426-23
10.1016/j.cell.2020.05.015
10.4049/jimmunol.169.8.4222
10.1586/erv.10.115
10.1038/s41423-022-00838-5
10.1101/2021.09.29.462373
10.3390/pathogens8030133
10.1038/s41586-020-2622-0
10.1128/JVI.00687-09
10.1038/s12276-021-00604-z
10.1093/infdis/jiu003
10.1128/JVI.00903-07
10.1038/s41591-020-0901-9
10.1056/NEJMc2103740
10.1126/science.abg7404
10.1038/s41423-021-00743-3
10.1056/NEJMoa2034577
10.1016/j.cell.2022.01.019
10.1016/j.immuni.2020.04.023
10.3390/v6062328
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
NPM
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.3390/vaccines13040411
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection (ProQuest)
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Engineering Research Database
ProQuest Central Student
ProQuest Research Library
ProQuest SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef

Publicly Available Content Database

MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ) (Open Access)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_4821fd361b5245f68bff04fb91e04cbe
PMC12031414
A837691797
40333327
10_3390_vaccines13040411
Genre Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: Geovax
– fundername: GSU Institutional funds
GroupedDBID 53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
AAYXX
ABUWG
ADBBV
AEUYN
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
NPM
PMFND
3V.
7T7
7XB
8FD
8FK
C1K
COVID
FR3
MBDVC
P64
PKEHL
PQEST
PQGLB
PQUKI
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c513t-ad77739a0128bd5695e70a3fa89e4a86856e748aa1a53155f2f9617ac8fe080f3
IEDL.DBID M48
ISSN 2076-393X
IngestDate Wed Aug 27 01:15:16 EDT 2025
Thu Aug 21 18:26:45 EDT 2025
Fri Jul 11 18:27:28 EDT 2025
Fri Jul 18 07:11:25 EDT 2025
Fri May 16 01:11:03 EDT 2025
Tue Jun 10 20:53:45 EDT 2025
Thu May 15 23:20:39 EDT 2025
Tue Jul 01 05:02:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords COVID-19
SARS-CoV-2
MVA-VLP
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c513t-ad77739a0128bd5695e70a3fa89e4a86856e748aa1a53155f2f9617ac8fe080f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0009-0003-3645-5605
0000-0003-2314-3437
0000-0003-0970-4875
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/vaccines13040411
PMID 40333327
PQID 3194648484
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_4821fd361b5245f68bff04fb91e04cbe
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12031414
proquest_miscellaneous_3201398014
proquest_journals_3194648484
gale_infotracmisc_A837691797
gale_infotracacademiconefile_A837691797
pubmed_primary_40333327
crossref_primary_10_3390_vaccines13040411
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-04-15
PublicationDateYYYYMMDD 2025-04-15
PublicationDate_xml – month: 04
  year: 2025
  text: 2025-04-15
  day: 15
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Vaccines (Basel)
PublicationTitleAlternate Vaccines (Basel)
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References ref_50
Gasteiger (ref_31) 2007; 81
ref_13
Moderbacher (ref_17) 2020; 183
Shen (ref_32) 2002; 169
ref_55
McMahan (ref_6) 2021; 590
ref_54
Kumar (ref_43) 2014; 6
Arieta (ref_52) 2023; 186
Tan (ref_19) 2020; 14
Polack (ref_5) 2020; 383
Gherardi (ref_38) 2000; 74
Yang (ref_11) 2022; 4
ref_25
Tan (ref_23) 2021; 34
Hachmann (ref_9) 2022; 387
Liao (ref_15) 2020; 26
Altmann (ref_21) 2021; 371
Rothan (ref_46) 2020; 547
ref_28
ref_27
Miura (ref_56) 2023; 97
Goepfert (ref_33) 2011; 203
Shen (ref_7) 2021; 384
Wyatt (ref_41) 2009; 83
Buchholz (ref_53) 2004; 101
Oja (ref_16) 2020; 50
Sekine (ref_18) 2020; 183
ref_36
ref_35
ref_30
Grifoni (ref_24) 2020; 181
Mellado (ref_26) 2010; 9
Kastenmuller (ref_29) 2006; 350
Guo (ref_51) 2024; 5
Goepfert (ref_34) 2014; 210
ref_39
Singh (ref_1) 2021; 53
Chiuppesi (ref_22) 2022; 7
Gherardi (ref_37) 2000; 74
Ni (ref_20) 2020; 52
Baden (ref_3) 2021; 384
Cui (ref_8) 2022; 185
Cao (ref_10) 2022; 608
Corbett (ref_4) 2020; 586
ref_45
ref_44
ref_42
ref_2
ref_49
Malherbe (ref_40) 2020; 5
ref_48
Choi (ref_12) 2022; 19
Bertoletti (ref_14) 2021; 18
Kumar (ref_47) 2013; 87
References_xml – ident: ref_55
  doi: 10.1074/jbc.RA120.016175
– ident: ref_36
  doi: 10.1038/s41598-017-19041-y
– volume: 547
  start-page: 7
  year: 2020
  ident: ref_46
  article-title: The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-CoV-2) replication and attenuates inflammation in human cells
  publication-title: Virology
  doi: 10.1016/j.virol.2020.05.002
– volume: 14
  start-page: 746
  year: 2020
  ident: ref_19
  article-title: Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
  publication-title: Front. Med.
  doi: 10.1007/s11684-020-0822-5
– ident: ref_30
  doi: 10.1038/s41598-017-08719-y
– volume: 183
  start-page: 158
  year: 2020
  ident: ref_18
  article-title: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
  publication-title: Cell
  doi: 10.1016/j.cell.2020.08.017
– volume: 74
  start-page: 7651
  year: 2000
  ident: ref_38
  article-title: Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector
  publication-title: J. Virol.
  doi: 10.1128/JVI.74.16.7651-7655.2000
– volume: 101
  start-page: 9804
  year: 2004
  ident: ref_53
  article-title: Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0403492101
– volume: 590
  start-page: 630
  year: 2021
  ident: ref_6
  article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques
  publication-title: Nature
  doi: 10.1038/s41586-020-03041-6
– ident: ref_49
  doi: 10.1038/d41586-021-02177-3
– ident: ref_48
  doi: 10.3390/pathogens13070528
– volume: 5
  start-page: 78
  year: 2020
  ident: ref_40
  article-title: Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection
  publication-title: npj Vaccines
  doi: 10.1038/s41541-020-00226-y
– ident: ref_28
  doi: 10.1186/1471-2172-9-15
– volume: 87
  start-page: 3655
  year: 2013
  ident: ref_47
  article-title: Inflammasome adaptor protein Apoptosis-associated speck-like protein containing CARD (ASC) is critical for the immune response and survival in west Nile virus encephalitis
  publication-title: J. Virol.
  doi: 10.1128/JVI.02667-12
– ident: ref_13
  doi: 10.3390/vaccines10030442
– volume: 384
  start-page: 403
  year: 2021
  ident: ref_3
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
– ident: ref_42
  doi: 10.1101/2020.12.14.422714
– volume: 350
  start-page: 276
  year: 2006
  ident: ref_29
  article-title: Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity
  publication-title: Virology
  doi: 10.1016/j.virol.2006.02.039
– volume: 34
  start-page: 108728
  year: 2021
  ident: ref_23
  article-title: Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.108728
– volume: 5
  start-page: e24
  year: 2024
  ident: ref_51
  article-title: Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: A longitudinal cohort study
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(23)00255-0
– volume: 4
  start-page: 228
  year: 2022
  ident: ref_11
  article-title: Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination
  publication-title: Biosaf. Health
  doi: 10.1016/j.bsheal.2022.07.001
– volume: 203
  start-page: 610
  year: 2011
  ident: ref_33
  article-title: Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiq105
– volume: 50
  start-page: 1998
  year: 2020
  ident: ref_16
  article-title: Divergent SARS-CoV-2-specific T-and B-cell responses in severe but not mild COVID-19 patients
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.202048908
– volume: 387
  start-page: 86
  year: 2022
  ident: ref_9
  article-title: Neutralization escape by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4, and BA. 5
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2206576
– ident: ref_39
  doi: 10.1038/s41598-017-15039-8
– volume: 186
  start-page: 2392
  year: 2023
  ident: ref_52
  article-title: The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection
  publication-title: Cell
  doi: 10.1016/j.cell.2023.04.007
– ident: ref_25
  doi: 10.3389/fbioe.2020.00862
– ident: ref_54
  doi: 10.3389/fimmu.2022.827605
– ident: ref_50
  doi: 10.1101/2023.01.03.519511
– volume: 74
  start-page: 923
  year: 2000
  ident: ref_37
  article-title: Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine
  publication-title: J. Virol.
  doi: 10.1128/JVI.74.2.923-933.2000
– volume: 183
  start-page: 996
  year: 2020
  ident: ref_17
  article-title: Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
  publication-title: Cell
  doi: 10.1016/j.cell.2020.09.038
– ident: ref_44
  doi: 10.3389/fmicb.2024.1466980
– volume: 608
  start-page: 593
  year: 2022
  ident: ref_10
  article-title: 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection
  publication-title: Nature
  doi: 10.1038/s41586-022-04980-y
– volume: 7
  start-page: 7
  year: 2022
  ident: ref_22
  article-title: Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
  publication-title: npj Vaccines
  doi: 10.1038/s41541-022-00436-6
– ident: ref_27
  doi: 10.3389/fimmu.2020.01100
– volume: 97
  start-page: e0042623
  year: 2023
  ident: ref_56
  article-title: Distinct motifs in the E protein are required for SARS-CoV-2 virus particle formation and lysosomal deacidification in host cells
  publication-title: J. Virol.
  doi: 10.1128/jvi.00426-23
– volume: 181
  start-page: 1489
  year: 2020
  ident: ref_24
  article-title: Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.015
– volume: 169
  start-page: 4222
  year: 2002
  ident: ref_32
  article-title: Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.169.8.4222
– volume: 9
  start-page: 1149
  year: 2010
  ident: ref_26
  article-title: Virus-like particles in vaccine development
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/erv.10.115
– volume: 19
  start-page: 447
  year: 2022
  ident: ref_12
  article-title: T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-022-00838-5
– ident: ref_45
  doi: 10.1101/2021.09.29.462373
– ident: ref_35
  doi: 10.3390/pathogens8030133
– volume: 586
  start-page: 567
  year: 2020
  ident: ref_4
  article-title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
  publication-title: Nature
  doi: 10.1038/s41586-020-2622-0
– volume: 83
  start-page: 7176
  year: 2009
  ident: ref_41
  article-title: Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection
  publication-title: J. Virol.
  doi: 10.1128/JVI.00687-09
– volume: 53
  start-page: 537
  year: 2021
  ident: ref_1
  article-title: On the origin and evolution of SARS-CoV-2
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-021-00604-z
– volume: 210
  start-page: 99
  year: 2014
  ident: ref_34
  article-title: Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiu003
– volume: 81
  start-page: 11925
  year: 2007
  ident: ref_31
  article-title: Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines
  publication-title: J. Virol.
  doi: 10.1128/JVI.00903-07
– volume: 26
  start-page: 842
  year: 2020
  ident: ref_15
  article-title: Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0901-9
– ident: ref_2
– volume: 384
  start-page: 2352
  year: 2021
  ident: ref_7
  article-title: Neutralization of SARS-CoV-2 variants B. 1.429 and B. 1.351
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2103740
– volume: 371
  start-page: 1103
  year: 2021
  ident: ref_21
  article-title: Immunity to SARS-CoV-2 variants of concern
  publication-title: Science
  doi: 10.1126/science.abg7404
– volume: 18
  start-page: 2307
  year: 2021
  ident: ref_14
  article-title: SARS-CoV-2-specific T cells in infection and vaccination
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-021-00743-3
– volume: 383
  start-page: 2603
  year: 2020
  ident: ref_5
  article-title: Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2034577
– volume: 185
  start-page: 860
  year: 2022
  ident: ref_8
  article-title: Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.019
– volume: 52
  start-page: 971
  year: 2020
  ident: ref_20
  article-title: Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.04.023
– volume: 6
  start-page: 2328
  year: 2014
  ident: ref_43
  article-title: Infection with non-lethal West Nile virus Eg101 strain induces immunity that protects mice against the lethal West Nile virus NY99 strain
  publication-title: Viruses
  doi: 10.3390/v6062328
SSID ssj0000913867
Score 2.31421
Snippet Widespread and rapidly evolving SARS-CoV-2 posed an unprecedented challenge to vaccine developers. GeoVax has designed a multiantigen SARS-CoV-2 vaccine,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 411
SubjectTerms Animals
Antibodies
Antigens
COVID-19
COVID-19 vaccines
Effectiveness
Enzymes
Genes
Immune response
Immunogenicity
Infections
Lungs
Lymphocytes
Lymphocytes T
Microscopy
MVA-VLP
Olfactory bulb
Peptides
Proteins
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Transgenic mice
Vaccine efficacy
Vaccines
Viral diseases
Viruses
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ja9wwFBYlp15K97pNigolpRARW5ulozskhNKUoUmG3IRsS52B4Cm1E8i_z3u2Mxm3h15q3yzZlvR2Ld8j5GNVgxWwIjAuasmkr3NWghVkVtnAyzLo2E-4nX7XJxfy66W63Er1hXvCBnjgYeAOpeFZrIXOSsWlitqUMaYyljYLqazKgNoXbN5WMNXrYJsJo_NhXVJAXH944ytcqW5BZ8tUZtnEDvVw_X8r5S2rNN0xuWWCjp-SJ6PvSIuhzc_Io9A8J_vzAXz69oCeP5ylag_oPp0_wFLfviA3_VlbVjQdAnDSxQr-wBb9pH2o6WJoOJ0PuA0tLX76FbiO9Kz4ccZm6wXj1DdYDzi2gfJVQz39FroltGhZzI447c0efHpV0dP1dRso5lm7ekkujo_OZydszLrAKpWJjgG58lxYj5arrJW2KuSpF9EbG6Q32igdcmm8zzzIr1KRRwtukK9MDOB-RvGK7DTrJrwhFJSpVT63ugInIrXGxuCNRPKBmyOlTcjnexq4XwO4hoOgBOnl_qRXQr4gkTb1EBa7fwDM4kZmcf9iloR8QhI7FF6gY-XHMwjQXITBcgWE6xoCWJsnZHdSE4SumhbfM4kbhb51oM2klgbuhHzYFOObuJGtCTD0TnD0uRGyJyGvB57adEmmAi4OHzcTbpv0eVrSrJY9JHjGMQ1BJt_-j1F6Rx5zzHKMiJZql-x0v6_DHrheXfm-l7I7mUQr8Q
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da50wFA9b-7KXse-5dSOD0TFoqMYkJk_DXm4pYy2Xflz6JlGTXqFoV28L_e93jnrvrRtM30zU6Pk-SX6HkK9FCVbAxI7xuBRM2DJhOVhBZqRxPM-d8l3C7fhEHV2In5fycki4tcOyypVO7BR12RSYI98HVhFKaDh_3PxmWDUKZ1eHEhpPyTaoYA3B1_bB9GR2us6yIOqlVkk_PxlDfL9_bwucsW5Bd4tQRNHIHnWw_f8q50fWabxy8pEpOnxBng8-JE17or8kT1z9iuzOehDqhz16vtlT1e7RXTrbwFM_vCb33Z5bltZLBOKk8wrewOZd8t6VdN4PnM56_IaWple2AheSnqWnZ2zSzBmntsZ-wLk1tFc1tfSXWy5gRIt0MuW0M3_w6Kqgx81d6yjWW7t-Qy4Op-eTIzZUX2CFjOIlA7IlSWwsWrC8lMpIl4Q29lYbJ6xWWiqXCG1tZEGOpfTcG3CHbKG9AzfUx2_JVt3U7j2hoFSNtIlRBTgTodHGO6uFD4UHd0cIE5DvKxpkNz3IRgbBCdIr-5teATlAIq37ITx2d6G5vcoGacuE5pEvYxXlkgvplc49vi03kQtFkbuAfEMSZyjEQMfCDnsRYLgIh5WlELYrCGRNEpCdUU8QvmLcvGKSbBD-NtuwakC-rJvxTlzQVjv49VnM0fdG6J6AvOt5av1JIozh4PBwPeK20TePW-pq0UGDRxzLEUTiw__H9ZE841jHGDEr5Q7ZWt7euU_gXC3zz4ME_QFltiR0
  priority: 102
  providerName: ProQuest
Title Multi-Antigen Viral-Vectored Vaccine Protects Against SARS-CoV-2 and Variants in a Lethal hACE2 Transgenic Mouse Model
URI https://www.ncbi.nlm.nih.gov/pubmed/40333327
https://www.proquest.com/docview/3194648484
https://www.proquest.com/docview/3201398014
https://pubmed.ncbi.nlm.nih.gov/PMC12031414
https://doaj.org/article/4821fd361b5245f68bff04fb91e04cbe
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Nb9MwFLfQduGC-CZjVEZCQ0gzNP5I7ANCWdVpQnSqtrXqLXISe600pdB2E_3veS9J2wV2ILnFjmPnfTt5v0fIh7wAK2CEY1wUkklbxCwDK8iMMo5nmYt8teE2OI_ORvL7RE126dHNC1w-GNphPanR4ubz71_rbyDwXzHihJD9y53N8SP0EtSx7EpM9N0HuxSjmA4aZ7_SyyYUuiopyyF4Z8KISf3d8sFBWnaqgvP_V2nfs1rtPyrvmajTp-RJ41vSpGaGZ-SRK5-To2ENTr0-ple7XKvlMT2iwx1s9foFuatycVlSrhCgk45n8AQ2rjb1XUHH9cTpsMZ1WNLk2s7AtaSXycUl683HjFNbYj_g6BLaZyW19IdbTWFG06TX57QyizD0LKeD-e3SUazDdvOSjE77V70z1lRlYLkKxYoBOeNYGIuWLStUZJSLu1Z4q42TVkdaRS6W2trQgnwr5bk34CbZXHsH7qkXr8heOS_dG0JB2RplYxPl4GR0jTbeWS19V3pwg6Q0Afm0oUH6swbfSCFoQXqlf9MrICdIpG0_hM2uLswX12kjhanUPPSFiMJMcal8pDOPT8tM6Loyz1xAPiKJU2Q3oGNumxwFmC7CZKUJhPMRBLgmDshhqycIZd5u3jBJuuHpFLSdjKSGMyDvt814J_7oVjp49ang6JMjpE9AXtc8tV2S7Ao4OAyuW9zWWnO7pZxNK8jwkGOZglAe_PcC35LHHEsdI6ylOiR7q8Wtewf-1yrrkP2T_vnwolPtX3QqIfsDGVAv-g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZG9wAviDuBAUaCIaRZS3xJ7AeEstJpY21VbV21t8xJ7LUSSsfSDfVP8Rs5TnpZQOJtyVvs2Cc5V9--g9CHLAcvoJghlOWccJ1HJAUvSJRQhqapCW014dbrhwen_PuZONtAv5dnYdy2yqVNrAx1Ps3cHPkuiAoPuYT76-VP4rJGudXVZQqNWiyOzPwXDNnKL4ffgL8fKd3vDNsHZJFVgGQiYDMC5EQRU9pZ5jQXoRIm8jWzWirDtQylCE3EpdaBBvkUwlKrwM3rTFoD4ZVl0O49tMkZDGVaaHOv0x8cr2Z1HMqmDKN6PZQx5e_e6MytkJfgK7jPg6Dh_6o0Af86g1vesLlT85br23-EHi5iVhzXQvYYbZjiCdoe1KDX8x08XJ_hKnfwNh6s4bDnT9FNdcaXxMXMAX_i0QR6IKNqscDkeFQTjgc1XkSJ4ws9gZAVn8THJ6Q9HRGKdeHqgaYUUD4psMZdMxsDReO43aG4crfQ9CTDvel1abDL7_bjGTq9E748R61iWpiXCIMRV0JHKswgePGVVNZoya3PLYRXnCsPfV7yILmsQT0SGAw5fiV_88tDe45Jq3oOjrt6ML26SBbanXBJA5uzMEgF5cKGMrWut1QFxudZajz0ybE4cUYD-JjpxdkHINfBbyWxBDsPA2cVeWirUROUPWsWL4UkWRibMlmrhofer4rdm24DXWHg1yeMuljfQQV56EUtU6tP4j6Di0LjsiFtjW9ulhSTcQVFHlCX_iDgr_5P1zt0_2DY6ybdw_7Ra_SAuhzKDi9TbKHW7OravIHAbpa-XWgTRud3rcB_APILYIE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyFeEHcCA4wEQ0izmjhOYj8glHWtNnZRtUu1t-Ak9loJpWPphvrX-HWck6TtAhJvS95ixz7Jufr2HUI-ZDl4AeUbxv1cMKHziKXgBZkKlOFpakJbTbgdHoW7Z-LbeXC-Rn4vzsLgtsqFTawMdT7NcI68C6IiQiHh7tpmW8RwZ_D18ifDDFK40rpIp1GLyL6Z_4LhW_llbwd4_ZHzQf-0t8uaDAMsCzx_xoC0KPKVRiud5kGoAhO52rdaKiO0DGUQmkhIrT0NshoEllsFLl9n0hoItawP7d4j6xGMitwOWd_uHw2PlzM8iLgpw6heG_V95XZvdIar5SX4DeEKz2v5wiplwL-O4ZZnbO_avOUGB4_IwyZ-pXEtcI_JmimekM1hDYA936Knq_Nc5RbdpMMVNPb8KbmpzvuyuJghCCgdTaAHNqoWDkxORzXhdFhjR5Q0vtATCF_pSXx8wnrTEeNUF1gPtKaA8klBNT0wszFQNI57fU4r1wtNTzJ6OL0uDcVcbz-ekbM74ctz0immhXlJKBh0FehIhRkEMq6SyhothXWFhVBLCOWQzwseJJc1wEcCAyPkV_I3vxyyjUxa1kNo7urB9OoiaTQ9EZJ7NvdDLw24CGwoU4u9pcozrshS45BPyOIEDQjwMdPNOQggF6G4kliCzYdBtIocstGqCYqftYsXQpI0hqdMVmrikPfLYnwTN9MVBn594nOM-xE2yCEvaplafpJwfbg4NC5b0tb65nZJMRlXsOQex1QInnj1f7rekfuguMnB3tH-a_KAYzplhM4MNkhndnVt3kCMN0vfNspEyfe71t8_Zo9ktg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multi-Antigen+Viral-Vectored+Vaccine+Protects+Against+SARS-CoV-2+and+Variants+in+a+Lethal+hACE2+Transgenic+Mouse+Model&rft.jtitle=Vaccines+%28Basel%29&rft.au=Stone%2C+Shannon&rft.au=Elsharkawy%2C+Amany&rft.au=Burleson%2C+J.+D&rft.au=Hauser%2C+Mary&rft.date=2025-04-15&rft.pub=MDPI+AG&rft.issn=2076-393X&rft.volume=13&rft.issue=4&rft_id=info:doi/10.3390%2Fvaccines13040411&rft.externalDocID=A837691797
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon